Analysis of the impact of different schemes of preparation to trabeculectomy on the healing markers on the Tenon fibroblasts cultures

Sci Rep. 2023 Sep 28;13(1):16353. doi: 10.1038/s41598-023-43246-z.

Abstract

The aim of the study was to assess the influence of different regimes of patient's preparation before trabeculectomy on the markers of healing process in Tenon's fibroblast cultures.The studied group consisted of 66 patients with open angle glaucoma undergoing primary trabeculectomy. The patients were divided into 5 groups with different regimes of preparation before the surgery based on application or withdrawal of topical antiglaucoma medications and steroids (G1-patients using antiglaucoma drops until the day of the surgery; G2-patients using antiglaucoma drops until the day of the surgery and additionally dexamethasone for 4 weeks before surgery; G3-patients who stopped using antiglaucoma drops 4 weeks before the surgery and introduced dexamethasone for 4 weeks before surgery; G4-patients who stopped using antiglaucoma drops 4 weeks before the surgery; G5-control group, patients with newly diagnosed glaucoma in whom trabeculectomy was the first treatment option without medical treatment). During trabeculectomy the samples of Tenon's capsule were obtained. Tenon fibroblasts were isolated directly from the explants to test their proliferation ability and the level of released healing markers. Following factors typical of healing process were evaluated using commercially available ELISA kits: IL 1-β, IL-6, IL-8, VEGF-A, TGF-β1 and MMP-9. Concentrations of IL-1β, IL-6 and TGF-β1 were significantly higher in the group obtaining antiglaucoma drops. Additionally, in this group the fibroblasts revealed the highest proliferation potential, indicating the active healing process. The levels of IL-8, VEGF-A and MMP-9 were similar between the groups. Our study shows that for the best conjunctival anti-inflammatory control, the most influential factor is the withdrawal of antiglaucoma medications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiglaucoma Agents
  • Cells, Cultured
  • Conjunctiva
  • Dexamethasone / pharmacology
  • Fibroblasts
  • Glaucoma, Open-Angle* / surgery
  • Humans
  • Interleukin-6
  • Interleukin-8
  • Matrix Metalloproteinase 9
  • Trabeculectomy*
  • Transforming Growth Factor beta1
  • Vascular Endothelial Growth Factor A

Substances

  • Transforming Growth Factor beta1
  • Matrix Metalloproteinase 9
  • Interleukin-6
  • Antiglaucoma Agents
  • Vascular Endothelial Growth Factor A
  • Interleukin-8
  • Dexamethasone